Peptide News

The emergence of bacterial antibiotic resistance against limited therapeutic options is prompting research into the discovery and optimization of alternative therapies such as cyclic antimicrobial peptides.

Scientists at the Tisch Cancer Institute developed an immunotherapy based on intra-tumor administration of Flt3L and the oncolytic Newcastle Disease Virus (NDV) to improve recruiting and activating dendritic cells.

The potential of cytokines as immunotherapies is limited by their systemic toxicity, therefore, new engineering approaches aim at modifying cytokines for tumor-targeted reconstitution of their activity, providing new opportunities for their use in combina

Learn how investigators at George Washington University Cancer Center leveraged synthetic peptides to activate and amplify patient-derived T cells to generate specific T cell immunotherapies for medulloblastoma.

SARS-CoV-2 vaccines have reduced efficiency against variants of concern. Find out how antibody and T cell responses are affected by variant associated mutations.

Learn about the potential for adverse immunological reactions associated with the therapeutic use of CRISPR/Cas9, which may include B and T cell responses.

Learn about how vaccine or infection-induced T cell responses against the original SARS-CoV-2 strain remain protective against new variants.

Learn about a new approach to the treatment of Parkinson's disease alpha-synuclein pathology that uses a cell-penetrating peptide to induce proteasome degradation of alpha-synuclein.

Non-Coding Sequences Expand Neoantigens for Therapy

How the Proteasome Modulates the Immunopeptidome